Molecule to Market Position Penn Pharma as a single source CDMO that can take a compound from early development through to commercial manufacture. This molecule to market capability enables clients to accelerate timelines with integrated formulation development, analytical development, clinical trial supply, and manufacturing under one roof.

Potent Molecule Capability Leverage potent and contained manufacturing to manage high safety profile programs and complex handling. Penn's MHRA licensed facilities, FDA inspections, and UK Home Office licensing for controlled drugs signal strong regulatory reliability for global partners.

Global Regulatory Footprint Benefit from a proven global regulatory footprint with experience delivering products and supply across Europe, the USA, South America and Japan. This helps sponsors navigate regulatory challenges and access multiple international markets with compliant cross border operations.

Flexible Capacity Capitalize on recent expansions including a purpose built contained manufacturing facility and large scale commercial suite that provide flexible capacity and the ability to service a broad range of scales and dosage forms.

Full Service Offering Access a broad service suite from formulation and analytical development to packaging, clinical trial material distribution, specials manufacturing, supply chain management, QA and QP release. This end to end offering reduces vendor coordination and supports efficient product launches.